Dr. Franzusoff joined PACT Pharma in Jan, 2017. For the past 2 years, he had been consulting for several private and public biotech/pharma companies in the I-O space, in addition to his role as founder and CEO of Krypton Immuno-oncology. At Bavarian Nordic, he worked at the forefront of the electrified I-O space as SVP R&D, which resulted in the $1B deal with BMS for Prostvac, its Ph3 cancer immunotherapy product. He had returned to California for that role, from Boston, after serving as Chief Executive Officer and Board Director for AZTherapies, developing Alzheimer’s therapies based on re-purposing previously approved drugs via the 505(b)2 pathway for Phase 3 studies. He previously led the venture-backed Permeon Biologics as President and a member of the board of directors. Dr. Franzusoff’s career in the biotechnology industry was launched with the co-founding of the biotech GlobeImmune, Inc., where he served as Vice President of Research & Development for immunotherapy against cancer & infectious diseases. He was a tenured Associate Professor at the University of Colorado, School of Medicine until 2004.
Dr. Franzusoff received his PhD in Biochemistry from SUNY at Stony Brook, NY. Dr. Franzusoff trained as a Postdoctoral Fellow with the Nobel Laureate, Dr. Randy Schekman, at the University of California, Berkeley. He is the author/co-author of numerous publications and inventor/co-inventor on numerous patents in diverse fields.